Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy
Aquestive's Anaphylm, which is set for an imminent FDA filing, has blockbuster potential. See why I think AQST stock is a buy ...
Tonix Pharmaceuticals: FDA AdCom News Positive, But Making Bull Case Is Problematic
Tonix Pharma (TNXP) has submitted an NDA for its candidate TNX-102 SL for fibromyalgia, with a PDUFA date set for August 15, 2025. See why I'm on the sidelines.